California Department of Public Health Immunization Updates for Providers

Friday, March 8, 2024

9:00AM - 10:30AM



Questions

During today's webinar, please use the Q&A panel to ask your questions so CDPH subject matter experts can respond directly.





Note: CDPH SMEs and Panelists on today's call will do their best to answer all questions related to today's updates.



Housekeeping

Reminder to Panelists:



Please mute yourself when not speaking.

Please monitor the Q&A panel for questions you may be able to answer.

Reminder to Attendees:



Today's session is being recorded. For slides, webinar recordings, and other postings, see the

CDPH Weekly Immunization Updates for Providers



To be added to the CDPH email messaging listserv for providers, please email your request to billiedawn.greenblatt@cdph.ca.gov

If you have post-webinar-related questions, please email leslie.amani@cdph.ca.gov



Agenda: Friday, March 8, 2024

| No. | Item | Speaker(s) | Time (AM) |
|-----|--------------------------------------|---|--------------|
| 1 | Welcome, Announcements, and Poll | Leslie Amani and Cecilia Sandoval (CDPH) | 9:00 – 9:05 |
| 2 | COVID-19 Vaccine Administration Data | Celeste Romano (CDPH) | 9:05 – 9:10 |
| 3 | COVID-19 Testing Updates | Stefanie Medlin (CDPH) | 9:10-9:15 |
| 4 | Clinical Updates | Caterina Liu, MD (CDPH) | 9:15 - 9:25 |
| 5 | Therapeutics Update | Edward Salaguinto, PharmD, RPh (CDPH) | 9:25 - 9:30 |
| 6 | Vaccines for Children (VFC) | Christina Sapad (CDPH) | 9:30 - 9:40 |
| 7 | Vaccine Management | Amy Pine (My Turn) and Maria Volk (myCAvax) | 9:40 - 9:50 |
| 8 | Vaccines for Adults (VFA) | Lindsay Reynoso (CDPH) | 9:50 - 9:55 |
| 9 | Resources and Q&A | Leslie Amani (CDPH) | 9:55 – 10:30 |
| | Th | ank you! | |



Announcements

Leslie Amani, CDPH



Change: Provider Webinar Cadence

The CDPH Immunization Updates for Providers Webinar series is beginning a new cadence! The Friday webinars will move to a biweekly (every other Friday) cadence.

Meeting today Friday, March 8, 2024, from 9AM – 10:30AM

Next session: Friday, March 22, 2024, from 9AM – 10:30AM

Please continue to use the <u>CDPH Immunization Updates for Providers Zoom Registration Link</u> to join the sessions.

CDPH appreciates your continued attendance. Thank you for all that you are doing for the health and wellness of all Californians!





Sesame Care: COVID-19 Vaccine Appointments

The California COVID-19 telehealth program through Sesame Care officially ended on Thursday, February 29, 2024.

Sesame Care in partnership with CDPH will be offering \$30 COVID-19 vaccine appointments for California residents.

Visit https://sesamecare.com/covidca and use the promo code **CACOVID** to get the discounted rate.

FREE Virtual COVID-19 Visit for Californians Ages 12 and Up

PARA ESPAÑOL, OPRIMA AQUÍ. Pick an appointment below to connect with a FREE healthcare provider who can prescribe you COVID-19 medications if appropriate. COVID-19 medications (Paxlovid or Lagevrio) are safe and effective and can help prevent you from getting severely ill. For information on how to get free COVID-19 medications or assistance with your co-pay, see the FAQ section below.

Language support: All providers have access to a translation service - view supported languages here.

Please note, this is a free service provided by the California Department of Public Health to support uninsured and underinsured individuals within the State of California who cannot connect with a healthcare provider within 24 hours of receiving a positive test result or developing symptoms and having history consistent with a COVID-19 diagnosis, such as close contact with a person confirmed positive. If you are insured, please try to reach vour healthcare provider first. If you have difficulty doing so within 24 hours of your positive result or symptoms starting, you may proceed with booking here. COVID-19 medications must be taken within 5 days of symptoms starting to be effective. Only make an appointment if you have a positive COVID-19 test or have symptoms and history consistent with a COVID-19 diagnosis. COVID-19 medications are only approved for those who have symptoms. If you need to get a COVID-19 test, visit https://covid19.ca.gov/get-tested/

**If you click away from this California-specific site, you will be entering Sesame Care's regular website which charges for its services. Californians who want free COVID-19 telehealth care will NOT be charged for the telehealth visit. Call +1 (888) 897-1244 if you have questions, need help booking an appointment or don't have an email address to use.





Respiratory Syncytial Virus (RSV) Fact Sheet

Vaccine Fact Sheet: Respiratory Syncytial Virus (RSV)



| Topic | Abrysvo TM | Arexvy |
|---------------------------------|---|---|
| Manufacturer | Pfizer | GSK |
| Product Info | Detailed prescribing information | Detailed prescribing information |
| Protects Against | RSV | RSV |
| Approved Ages | Individuals ≥60 years of age Pregnant individuals at 32-36 weeks gestational age | Individuals ≥60 years of age |
| Routine Schedule & Intervals | One dose for individuals 60 years of age and older using <u>shared</u> <u>clinical decision-making</u> . One dose for pregnant individuals at 32-26 weeks gestational age using seasonal administration (typically September to January). | One dose for individuals 60 years of age and older using shared clinical decision-making. |
| Administration | (IM) Intramuscular injection | (IM) Intramuscular injection |
| Packaging | Supplied in a kit that includes a vial of lyophilized antigen component, a prefilled syringe containing sterile water diluent component and a vial adapter. | Supplied in 2 vials that must be reconstituted prior to administration (lyophilized antigen component and adjuvant suspension). |
| | Supplied in cartons of 1, 5, or 10 kits. | Supplied in carton of 10 doses. |
| Dosage | 0.5mL single dose after reconstitution | 0.5mL single dose after reconstitution |
| Storage | Before reconstitution: | Before reconstitution: |
| | Store refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton. Preparation: | Adjuvant suspension component vial and lyophilized antigen component vials must be refrigerated at 2°C to 8°C (36°F to 46°F) in original package. |
| | Prepare by reconstituting the lyophilized antigen component (a sterile white powder) with the accompanying prefilled syringe containing sterile water diluent component. Do not freeze. Discard if the carton has been frozen. | Preparation: Prepare by reconstituting the lyophilized antigen component (a sterile white powder) with the accompanying adjuvan suspension component (an opalescent, colorless to pale brownish sterile liquid). |

California Department of Public Health, Immunization Branch

IMM-1511 (2/7/24)

Vaccine Fact Sheet: Respiratory Syncytial Virus (RSV)

| Topic | Abrysvo™ | Arexvy |
|------------------------------|---|--|
| | After reconstitution: Administer immediately or store at room temperature [15°C to 30°C (59°F to 86°F)]. Do not freeze reconstituted vaccine. | After reconstitution: Administer immediately or store between [2°C to 8°C (36°F to 46°F) or at room temperature up to 25°C (77°F) for up to 4 hours prior to use. Protect vials from light. Do not freeze. Discard if the adjuvant suspension component or antigen component has been frozen. |
| Expiration Date | 18 months from manufacture date | 24 months from manufacture date |
| Full ACIP Recommendations | RSV Vaccine ACIP Recommendations | RSV Vaccine ACIP Recommendations |
| VIS | RSV VIS | RSV VIS |
| Program Letter | VFA Letter | VFA Letter |
| Billing Codes | Billing Code 90471 NDC Codes 0069-0207-01, 0069-0250-01, 0069-0344-01, 0069-0344-05, 0069-0344-10, 0069-0344-21 HCPCS code: 90678 | Billing Code 90471 NDC Codes 58160-723-03, 58160-744-03, 58160-848-11 HCPCS code: 90679 |
| | See <u>Fall Respiratory Vaccine Codes</u> for more info | See <u>Fall Respiratory Vaccine Codes</u> for more info |
| Comments | Licensed in 2023 | Licensed in 2023 |

Refer to Vaccine Fact Sheets (EZIZ.org/Resources/VaccineFactSheets)

California Department of Public Health, Immunization Branch

This publication was supported by Grant Number H23/CCH922507 from the Centers for Disease Control and Prevention (CDC). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of CDC.





Immunization Fact Sheet: RSV – nirsevimab (Beyfortus™)

Immunization Fact Sheet: Respiratory Syncytial Virus (RSV)



IMM-1512 (2/7/24)

| Topic | Nirsevimab (Beyfortus™) | | |
|---------------------------------|--|--|--|
| Manufacturer | AstraZeneca and Sanofi | | |
| Product Info | <u>Detailed prescribing information</u> use links | | |
| Protects Against | Respiratory Syncytial Virus (RSV) | | |
| Approved Ages | PDA Licensed for: Neonates and infants born during or entering their first RSV season. Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season. | | |
| Routine Schedule & Intervals | dose for all infants <8 months born during or entering their 1st RSV season if: The birth parent did not receive RSV vaccine during pregnancy. The birth parent's RSV vaccination status is unknown. The infant was born within 14 days of prenatal RSV vaccination. | | |
| | 1 dose for infants and children 8–19 months old entering their 2nd RSV season and who are at increased risk for severe RSV: Native American/Alaska Native children Children with chronic lung disease of prematurity who required medical support (chronic corticosteroids, diuretics, or supplemental oxygen) any time during the 6-month period before the start of the second RSV season. Children who are severely immunocompromised. Children with cystic fibrosis who have either: | | |
| Administration | IM (intramuscular) injection. | | |
| Packaging | Pre-filled syringes: • 50mg (0.5mL) with purple plunger rod (for infants weighing <5 kg) • 100 mg (1mL) with light blue plunger rod Cartons of five pre-filled syringes: • Five 50 mg/0.5 mL single-dose pre-filled syringes in a carton • Five 100 mg/1 mL single-dose pre-filled syringes in a carton Packaging Images available at: <u>See packaging images</u> | | |
| Dosage | Age <8 months: Weight <5 kg: 50 mg dose (purple plunger rod) Weight ≥5 kg: 100 mg dose (light blue plunger rod) Age 8-19 months: 200 mg dose (2 separate 100 mg injections, at the same time at different sites | | |

Vaccine Fact Sheet: Respiratory Syncytial Virus (RSV) (Continued)

| Topic | Nirsevimab (Beyfortus [™]) |
|------------------------------|---|
| Recommended Timing | For infants born during RSV season: Within 1 week of birth. Infants with prolonged birth hospitalizations should receive nirsevimab shortly before or promptly after hospital discharge. For infants born outside of RSV season and children 8-19 months: Optimal administration is at the start of RSV season, usually October. Nirsevimab should be offered throughout the RSV season, typically October through March. For considerations of nirsevimab versus palivizumab for high-risk children, see: Nirsevimab (Beyfortus) Timing Guide |
| Shipping | Nirsevimab ships similarly to other pediatric routine vaccines. |
| Storage | Routine Storage: In a refrigerator at 2°C–8°C; DO NOT FREEZE. Short-term storage: Room temperature (20°C – 25°C), for 8 hours, if protected from light. |
| Use-by Limit | Nirsevimab has a shelf life of about 18 months. Once removed from the refrigerator, must be used within 8 hours or discarded. |
| Expiration Date | See packaging for expiration info. Nirsevimab can be returned after expiration, similar to other Sanofi vaccine products. See more for details. |
| Full ACIP Recommendations | Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children MMWR |
| VIS | Information Immunization Statement |
| Program Letter | <u>VFC Letter</u> |
| Billing Codes | NDC Code(s): 49281-574-15, 49281-574-88, 49281-575-00, 49281-575-15 https://www.cdc.gov/vaccines/programs/iis/fall-season-respiratory-codes.html |
| Comments | Licensed in 2023 |

Refer to <u>Vaccine Fact Sheets</u> (EZIZ.org/Resources/VaccineFactSheets).

lifornia Department of Public Health, Immunization Branci

IMM-1512 (2/7/2

This publication was supported by Grant Number H23/CCH922507 from the Centers for Disease Control and Prevention (CDC), its contents are solely the responsibility of the authors and do not necessarily represent the official views of CDC.



California Department of Public Health, Immunization Branch



CA Immunization Coalition (CIC) Ed Hour


The California Immunization Coalition invites you to attend the next CIC Ed Hour which will feature the amazing team of Lydia Greene and Heather Simpson, the co-founders of Back to the Vax. Heather and Lydia who will share their journey as parent advocates and their work to share their experiences with practitioners and public health partners across the country.

When: Monday, March 11, 2024

Time: 12PM, PT

Registration link: Back to the Vax Zoom Registration Link











Equity-Centered Community Engagement by Public Health Departments: Lessons from the Field

The California Department of Public Health (CDPH) and many LHJs in California are working to be more inclusive of historically marginalized communities in their engagement and decision-making.

Building off of a recently-released research brief published by Onside Partners and ThinkForward Strategies in partnership with Blue Shield California Foundation, this webinar will explore what authentic community engagement by public agencies looks like and showcase inspiring examples from diverse California public health and education agencies that have successfully transformed their engagement strategies. These examples illustrate that meaningful change doesn't necessarily demand vast resources but rather requires strong leadership and internal capacity building. We will hear from state and local public health practitioners about their equity-centered community engagement practices and what they see as the keys to success. Audience members will also have the opportunity to share their own community engagement practices and ask questions to the speakers. This webinar is sponsored and co-hosted by Blue Shield of California Foundation.

Speakers:

- Dr. Rohan Radhakrishna, Deputy Director, CA Department of Public Health, Office of Health Equity
- Karen Ben-Moshe, Program Officer, Blue Shield of California Foundation
- Christine Fry, Principal, Onside Partners
- Practitioner Speakers To be announced

When: Tuesday, March 12, 2024

Time: 2PM – 3:15PM

Register: Equity-Centered Community Engagement by Public Health Departments: Lessons from the Field





CDPH Infection Prevention Webinars

CDPH Infection Prevention Webinars





The California Department of Public Health (CDPH)—with the California Association of Long Term Care Medicine (CALTCM), California Association of Health Facilities (CAHF), and Health Services Advisory Group (HSAG)—hosts a monthly (4th Wednesday) webinar on infection prevention for long term care facilities to discuss any recent updates on Coronavirus Disease 2019 (COVID-19) and provide a venue for addressing questions. The webinars focus on infection prevention guidance for SNFs. It is recommended that SNF infection prevention staff attend. Local health departments and SNF administrators, directors of nursing, and medical directors are also encouraged to attend. Please register in advance; space is limited. A recording link will be available the day following the webinar.

Day of the webinar event: Call-in telephone number for all webinars is: **415.655.0003**. You may join via computer (using your computer or telephone for audio) or by telephone only. (If you join the video portion of the webinar, for a better webinar experience we recommend you have Webex call your phone—don't dial in yourself).

Note: The CDPH 2nd Tuesday all-facilities phone calls have been discontinued for 2024.

Register for Upcoming Webinars





CDPH Infection Prevention Webinar



3:00 PM - 4:00 PM | Mar 27, 2024 (UTC-08:00) JoLynn Hinger



CDPH Webinars Registration Link for Webex





June 2024 California Immunization Coalition Summit



Audience: Physicians, pharmacists, nurses, administrators, educators, immunization stakeholders, coalition members, advocates and other providers from the public and private sector who are involved in working on current immunization issues, strategies and activities.

Location: Sacramento, CA

The 2024 California Immunization Coalition Summit will provide clinical updates and the latest information on issues related to vaccine administration and communication. Participating in this statewide event will provide access to the latest information on immunization issues and communication strategies and will help connect you with public health colleagues and private sector representatives that can assist your work in educating and supporting your community. The Summit is a terrific opportunity to renew our collective vision to make access to vaccinations and disease prevention a reality for all Californians.

California Immunization Coalition Annual Summit Registration Link





Poll: CAIR Naming: COVID-19 Vaccine Group

Question: What should CAIR name the new COVID-19 vaccine group under the recommendations section of CAIR?

- ☐ COVID-19 Annual
- □ COVID-19 Seasonal
- □ COVID-19 Updated





COVID-19 Vaccine Administration Data

Celeste Romano, CDPH




COVID-19 Vaccine Administration Summary

as of March 4, 2024

95,439,976


Total Doses Administered:

Daily Doses Administered: Statewide



5,479,909Total <u>Up-to-Date*</u> Recipients:

Percent of Population Who Are Up-to-Date



*Has received a dose of the Updated 2023-2024 vaccine




Trends in COVID-19 Vaccine Administration


as of March 4, 2024

Most Recent Eligibility Groups

 Additional Updated 2023-2024 dose for 65+ age group



Doses Administered by Age Group, Past 4 Weeks






Up-to-Date COVID-19 Vaccination Status Among 65+

by Race/Ethnicity* as of March 4, 2024

Highest uptake among NHPI**, White, and AIAN**

Uptake above state average in all 65+ race/ethnicity groups



*Vaccination rate estimates for some groups, such as NHPI, may be affected by differences in how demographic data is collected by the Census and at the time of vaccination **NHPI = Native Hawaiian and Pacific Islander, AIAN = American Indian or Alaska Native




Up-to-Date COVID-19 Vaccination Status Among 65+ by HPI

as of March 4, 2024

Highest uptake among Healthy Places Index quartiles 3&4

Uptake above state average in all Healthy Places Index quartiles



COVID-19 Vaccine Data Summary

as of March 4, 2024

Key Metrics

95.4 million doses administered

13.7% Statewide who are Up-to-Date

34.2% 65+ population Up-to-Date

+51 thousand doses administered

5.5 million Up-to-Date recipients

2.1 million 65+ Up-to-date recipients

System Notes

- Public dashboard is not yet updated to include the latest 2023-2024 guidelines
 - Updated monthly
- Email cdphvaccinedatateam@cdph.ca.gov for questions and comments



COVID-19 Testing Updates

Stefanie Medlin, CDPH, Medical Countermeasures



COVID-19 Testing Updates

<u>CDPH At-Home Testing Program:</u> As of February 29, 2024, the CDPH At-Home Testing Program has come to an end and COVID-19 at-home tests are no longer available to request from CDPH.

<u>Professional CLIA-waived tests:</u> Professional tests available to facilities with their own CLIA-waiver and state facility license through June 30, 2024. Eligible facilities would be Skilled Nursing Facilities, Long-Term Care Facilities and Community Clinics.

BinaxNOW CLIA-waived tests have extended expiration dates through July 2024.

We have depleted our inventory of COVID/Flu A&B multiplex tests. Should these tests become available again, we will notify this group of their availability.

Order professional CLIA-waived tests

here: https://labsupport.powerappsportals.us/ordercovidprofessionaluse/

For testing needs in an emergent scenario (outbreak etc.), please reach out to your local health department. Skilled Nursing Facilities and Long-Term Care Facilities may be eligible to receive tests through their local Medical Health Operational Area Coordinator (MHOAC). If you are an eligible facility, please contact your MHOAC for support: MHOAC Contact List



Additional Ways for Individuals to Obtain COVID-19 Tests

Insured? You may be eligible for tests. Read more here: https://covid19.ca.gov/get-tested/

Fall 2023, U.S. households can order free COVID-19 tests mailed to their home: https://www.covid.gov/tests *The LAST day to order tests through USPS is March 8, 2024. If you have not yet placed an order for tests through the federal government, since November 20, 2023, you have until the end of the day on March 8th to order. After March 8th, tests will no longer be available.

Home Test to Treat offers free tests and free treatment (if eligible) for COVID-19 at home www.test2treat.org.* As of December 8, 2023, eligible individuals that sign up for Home Test to Treat will be sent COVID/Flu tests to use and home treatment options available will include COVID and Flu treatment (depending on the test result).

For questions, email OTCTesting@cdph.ca.gov



Clinical Update

Caterina Liu, MD, CDPH



Advisory Committee on Immunization Practices (ACIP) Meeting: February 28 – 29, 2024

- Vaccine topics with votes
 - COVID-19
 - Chikungunya
 - VFC Diphtheria, Tetanus, and Pertussis
- Other ACIP topics (no vote)
 - RSV vaccine
 - Influenza vaccine
 - Polio
 - Meningococcal
 - Pneumococcal
 - Vaxelis (combined DTaP, IPV, HIB, Hep B)

ACIP Meeting Presentations, February 28-29, 2024

ACIP Recent Meeting Recommendations

Interim Clinical Considerations for Use of COVID-19 Vaccines in the United States



CDC Recommends COVID-19 Vaccine Additional Dose for Adults 65+

CDC recommends that persons ≥ 65 years of age should receive an additional dose of 2023-2024 COVID-19 vaccine, at least 4 months after previous updated (2023-2024) COVID-19 vaccine dose

September 2023

- Updated 2023-2024 Vaccine (monovalent, XBB.1 component) recommended for all individuals 6 months+
- Recommendation for optional additional doses for all IC people

February 2024

 Recommendation for additional (second) dose for adults 65+



Guidance for Immunocompromised People

6 months-64 years

May receive additional updated doses 2 months following previous updated dose*

This guidance is unchanged

65+ years

Should receive 1 additional updated dose 2 months after previous updated dose*

This guidance is new


*Further additional doses may be administered, informed by the clinical judgement of a healthcare provider and personal preference and circumstances, at least 2 months after the last updated (2023–2024 Formula) COVID-19 vaccine dose.



Updated CDPH Timing Guide


English version IMM 1396


Spanish version IMM 1396S





Older Adults at Highest Risk of Severe COVID-19






Summary

- COVID-19 hospitalizations peaked in late December/early January; however, there are still approximately 20,000 new hospital admissions and 2,000 deaths due to COVID-19 each week
- Risk of severe illness due to COVID-19 continues throughout the year and is highest in those ≥65
 years
- Effectiveness of an additional dose in older adults has been demonstrated by past additional doses
- Receipt of 2023-2024 COVID-19 vaccine provides protection against JN.1 and other circulating variants, however vaccine effectiveness is expected to wane and additional dose in adults ≥65 years may restore protection that has waned since a fall vaccine dose
- Greatest benefit of a vaccine dose would be in those who have **not yet received a 2023-2024 dose**, particularly older adults and those with underlying medical conditions.

Looking Ahead: Revised Time Frame for 2024-2025 COVID-19 Vaccine Availability





ACIP Vote – Chikungunya vaccine

- <u>November 2023</u>: FDA approval of IXCHIQ (chikungunya vaccine), indicated for individuals at increased risk of exposure to chikungunya (single dose for adults 18+).
- February 2024: ACIP recommendations
 - Chikungunya vaccine is recommended for persons aged ≥18 years traveling to a country or territory where there is a chikungunya outbreak.
 - In addition, chikungunya vaccine may be considered for the following persons traveling to a country or territory without an outbreak but with evidence of chikungunya virus transmission among humans within the last 5 years
 - Persons aged >65 years, particularly those with underlying medical conditions, who are likely to have at least moderate exposure* to mosquitos, OR
 - Persons staying for a cumulative period of 6 months or more
 - Chikungunya vaccination is recommended for laboratory workers with potential for exposure to chikungunya virus.

*Moderate exposure could include travelers who might have at least 2 weeks (cumulative) of exposure to mosquitos in indoor and/or outdoor settings



ACIP VFC Vote - Diphtheria, Tetanus, Pertussis Vaccines

Background

- CDC recommends young children receive DTaP as the first dose in the diphtheria, tetanus, and pertussis childhood vaccination series (5 dose series)
- For children <7 years who develop a contraindication to DTaP, CDC previously recommended DT instead of DTaP
 - DT vaccine is no longer available in the United States
 - New guidance: for young children with a contraindication to pertussis-containing vaccines, vaccine providers may administer Td for all recommended remaining doses in place of DTaP

VFC resolution (vote):

- The addition of Td vaccine for use in children < 7 years of age for whom receipt of the pertussis component is contraindicated.
- Update the language regarding the Tdap booster to align with ACIP recommendations



Limited Td Supplies - CDC Guidance

- While Td vaccine supplies are constrained, providers should transition to use of Tdap vaccine in lieu of Td vaccine whenever possible, including when a tetanus booster is indicated for wound management.
- The limited supply of Td vaccine needs to be preserved for those with a <u>specific</u> contraindication to <u>pertussis-containing vaccines</u>.
 - (ACIP VFC Vote) For children <7 years who develop a contraindication to DTaP, vaccine providers may administer Td for all recommended remaining doses in place of DTaP

CDC Vaccines and Preventable Diseases (VPD): Diphtheria, Tetanus, and Pertussis

Vaccine Recommendations



Respiratory Syncytial Virus (RSV) Updates

- Safety review of potential risk of Guillain Barre Syndrome (GBS) in older adults (60+)
 - Estimated benefits of RSV vaccination outweigh potential risks when vaccination is implemented using the current recommendation that adults aged ≥60 years may receive RSV vaccination, using shared clinical decision-making
- Timing considerations for RSV vaccine in older adults (60+)
 - For unvaccinated adults, the best time to get vaccinated is in the late summer or early fall
- Policy issues to be addressed in June 2024
 - Moderna mRNA-1345 vaccine for use in adults aged ≥60 years
 - GSK RSV vaccine for use in adults aged 50-59 years at increased risk for RSV disease
 - Consideration of whether shared clinical decision-making remains the preferred policy option



Other ACIP Topics

Influenza

- Vaccination with a 2023-24 influenza vaccine <u>reduced the risk</u> for influenza outpatient visits and hospitalizations among all age groups across 22 US states
- Interim 2023-2024 vaccine effectiveness (VE) estimates from California public health data also show vaccine is protective
- o Various platforms and methods have yielded VE estimates for this season ranging from 45-67%
- Meningococcal Considerations for revision of the adolescent meningococcal vaccine schedule
- Pneumococcal New vaccine (PCV21) Phase 3 trials
- Polio Discussion of potential use of novel type 2 oral poliovirus vaccine (nOPV2) as an outbreak control measure in the U.S.
- Vaxelis (combined DTaP, IPV, HIB, Hep B) Considerations for use of Vaxelis in American Indian and Alaska Native infants



Therapeutics Update

Edward Salaguinto, PharmD, RPh, CDPH



Reminder: Paxlovid Emergency Use Authorization (EUA)

- On January 29, 2024, the FDA announced an important revision to the Paxlovid EUA stating that EUA-labeled Paxlovid distributed by the U.S. government will remain authorized for use only through March 8, 2024.
- After that date, all EUA-labeled Paxlovid needs to be returned or otherwise disposed.
 - o <u>www.PaxlovidEUAreturns.com</u>
 - PaxlovidEUAreturns@inmar.com
 - o call 877-740-6148
- The Paxlovid EUA will continue to authorize emergency use of the NDAlabeled Paxlovid for eligible pediatric patients 12 years of age and older weighing at least 88 pounds (40 kg).



Vaccines for Children (VFC)

Christina Sapad, CDPH



Limited Td Vaccine Supplies

- MassBiologics has discontinued production of TdVaxTM. Supply of TdVaxTM is anticipated to last through June.
- Sanofi, manufacturer of Tenivac®, is taking steps to augment their available supply of Td for the US and will be implementing ordering controls until the supply has increased.
- It is anticipated that the supply of Td vaccine in the US market will be constrained through 2024.
- Temporary ordering controls are in place in the public and private sectors. As a result, CDC has put allocations into place for all three Td vaccine presentations (Grifols vials; Sanofi vials; and Sanofi syringes).
- Due to the limited allocations, VFC providers can only request up to 10 doses of Td vaccine with your routine VFC vaccine order.
- Tetanus, diphtheria, and acellular pertussis (Tdap) vaccines are available without supply constraints at this time.



Limited Td Supplies - CDC Guidance

- Transition to use of Tdap vaccine in lieu of Td vaccine whenever possible while Td vaccine supplies are constrained, including when a tetanus booster is indicated for wound management.
- The limited supply of Td vaccine needs to be preserved for those with a <u>specific</u> contraindication to <u>pertussis-containing vaccines</u>.
 - (ACIP VFC Vote) For children <7 years who develop a contraindication to DTaP, vaccine providers may administer Td for all recommended remaining doses in place of DTaP

CDC Vaccines and Preventable Diseases (VPD): Diphtheria, Tetanus, and Pertussis

Vaccine Recommendations



Change to Pfizer Diluent

- Pfizer has changed the diluent pack size associated with CDC orders of Pfizer COVID-19 Vaccine (2023-2024 Formula) for ages 6 months through 4 years of age [59267-4315-02; COVID-19(Pfizer); (6m-4y); MDV3; 10-pk].
- Pfizer is now supplying diluent in a 25-pack.
 - Previously vaccine orders for this presentation were supplied with diluent in a 10-pack.
- Please note: One vial of diluent is required to reconstitute one multidose vial of vaccine for individuals 6 months through 4 years of age.
- For questions about diluent received with Pfizer COVID-19 Vaccine (2023-2024 Formula) for ages 6 months through 4 years of age, please contact Pfizer customer service at: **1-800-666-7248**, or


mrnavaccines@pfizer.com.

| Total Doses of Vaccine | Total Vials of Vaccine | Diluent Supplied | Number of Diluent Vials to be shipped |
|---------------------------|---------------------------|--------------------|--|
| 30 doses | 10 | 1 pack of 25 vials | 25 |
| 60 doses | 20 | 1 pack of 25 vials | 25 |
| 90 doses | 30 | 2 pack of 25 vials | 50 |
| 120 doses | 40 | 2 pack of 25 vials | 50 |



New Presentation and National Drug Code (NDC) for Hiberix

- The prior presentation of Hiberix (NDC 58160-0818-11, one vial of lyophilized antigen and one vial of diluent) is no longer available.
- It has been replaced with a new presentation of Hiberix (NDC 58160-0726-15, one vial of lyophilized antigen and one prefilled syringe of diluent) and has been made available for ordering through the VFC order form as of March 1, 2024.
- Please continue to use any remaining doses of the prior presentation of Hiberix before using the new presentation to ensure doses are not wasted.





Inactivated VFC Providers Due to Delinquent 2024 VFC Recertification

- 47 VFC Providers have been inactivated for not submitting their 2024 VFC Recertification.
 - o Due date was January 31, 2024, and multiple reminder communications have been sent.
- Medi-Cal and CHDP will be notified.
- If these providers are interested in enrolling in the VFC Program again, they can re-enroll during the next Recertification cycle in early 2025.

| County | # of Providers |
|----------------|----------------|
| ALAMEDA | 2 |
| CONTRA COSTA | 1 |
| FRESNO | 1 |
| LAKE | 1 |
| LOS ANGELES | 15 |
| MARIN | 2 |
| ORANGE | 9 |
| PLACER | 1 |
| RIVERSIDE | 2 |
| SAN BERNARDINO | 3 |
| SAN DIEGO | 2 |
| SAN MATEO | 1 |
| SANTA BARBARA | 1 |
| SANTA CLARA | 4 |
| TULARE | 1 |
| YOLO | 1 |
| Grand Total | 47 |





Poll: CAIR Naming: COVID-19 Vaccine Group

Question: What should CAIR name the new COVID-19 vaccine group under the recommendations section of CAIR?

- ☐ COVID-19 Annual
- □ COVID-19 Seasonal
- □ COVID-19 Updated



Vaccine Management


Amy Pine, My Turn, and Maria Volk, myCAvax



Super Clinics: Release 48 (1 of 2)

COMING





Clinic Managers and patients will be able to access the Super Clinic functionality with the My Turn R48 release on **Tuesday**, **March 26**, **2024**.







Super Clinics: Release 48 (2 of 2)




Patients will be able to schedule two or more appointments using the Super Clinic functionality.





Clinic Managers will be able to create Super Clinics and manage clinic inventory using the Super Clinic functionality.






Clinic Activation Reminder



Please ensure that your clinics are active for public appointments if you offer public scheduling. Log in to the system, navigate to the 'Clinics' tab and click the 'Activate Location' toggle on the clinic to display it on the public appointment booking website.





My Turn – Known Issues and Workarounds



Known Issues

Missing 'View More' Button in the Knowledge Center

✓ When a Clinic Manager or Vaccine Administrator attempted to access the 'All About My Turn' section of the Knowledge Center, we noticed that we were missing some knowledge articles. These articles were hidden behind the missing 'View More' button. We worked to get the button back on the page to get access to the rest of the articles.




Workaround/Next Steps

✓ Fixed: Wednesday, February 28, 2024



VFA and LHD 317 Programs Now Live in myCAvax!





Providers

What's New in myCAvax? - Release 45 (1 of 2)



New updates for providers launched on Tuesday, February 20, 2024!



Release Highlights



All providers must:

- Enter the storage unit's brand, model, the thermometer's model, and serial number and specify the vaccine stored (by Program name) in the unit while updating storage unit records
- Have at least one backup thermometer entered in the system while creating / updating storage units

All providers can:

- ✓ View the new warning message to upload the thermometer's certificate of calibration in the 'Uploaded Documents' tab when updating the thermometer type, model, serial number, or calibration expiration date
- View the updated 'Returns and Waste' label on the options / buttons instead of 'Waste'
- ✓ View the 'Inventory On-Hand' group header updated to 'Accountability' under the 'On-Hand Inventory' tab on vaccine order records
- Receive email communications when the thermometer's calibration expiration date is due or has passed the due date
- ✓ Use the new and updated multi-line transfer entry form introducing the new 'Transport Container' feature enabling them to enter multiple products in a single transfer entry

Providers enrolled in the Vaccines for Adults (VFA) / LHD 317 program can:

- √ View the new 'Vaccines for Adults / LHD 317' program tile on the home page
- ✓ Begin recertification by clicking the 'Recertify Locations' button visible in the 'Vaccines for Adults / LHD 317' program tile
- Enter / submit VFA / LHD 317 vaccine orders on the 'VFA / 317 Order Request' page; only one order can be placed during an ordering period
 - Note: Vaccine orders in the 'Draft' and 'Corrections Needed' statuses expire automatically after 14 days from the last modified date.
- Enter VFA / LHD 317 Returns and Waste Events on the 'VFA / LHD 317 Returns and Waste Events' page
- ✓ Enter VFA / LHD 317 Excursions on the 'VFA / LHD 317 Excursions' page
- Enter VFA / LHD 317 Shipment Incidents on the 'VFA / LHD 317 Shipment Incidents' page
- Enter VFA / LHD 317 Vaccine Transfers on the 'VFA / LHD 317 Transfers' page



Providers

What's New in myCAvax? - Release 45 (2 of 2)




New updates for providers launched on Tuesday, February 20, 2024!

Release Highlights



Providers enrolled in the VFA / LHD 317 program can:

- Receive email communications when the order gets approved or requires corrections
- ✓ Update and resubmit a vaccine order when the 'Corrections Needed' status has been set by the Customer Service Representative (CSR) following their review
- √ View the new 'Total Order Cost' field on the 'Order and Transfer Item' records





VFA Recertification Completion



Great work! 33% of VFA-eligible providers completed recertification so far.

As of **Thursday, March 7, 2024**, **180** VFA-eligible providers have completed recertification, out of **537** total providers eligible for VFA.





Workarounds to Complete Recertification Part Two





Issues

Missing LHD 317 / VFA tile on the Landing Page



Workaround/Next Steps

✓ If you do not see the LHD 317 or VFA tile on the landing page <u>and</u> you are the Primary VFA Contact or LHD 317 Vaccine Coordinator, contact the Provider Call Center.





Navigating to the Provider Location Account




Follow the steps below to navigate to your Provider Location and update storage units.

- 1. Navigate to the 'Program Locations' page.
- 2. Select 'View Program Location'.
- Select the 'Account Name'.
- Select the 'Related' tab and scroll until you see storage capacities.










Next Steps: Updating / Adding Storage Units for VFA




Providers will be required to update / add storage units during recertification.

If you have not yet completed recertification...

Update existing storage units by viewing historical data and copying appropriate information.



If you have already completed recertification, log in to myCAvax and make updates to existing storage units. Navigate to your Location Account and select the 'Related' tab to find the storage capacity section.






Action Required: Update Storage Units



All providers must update the storage units associated with their Provider Location. You will need to indicate what program vaccines are stored in the unit and update required thermometer and storage unit information.

If you do not update your storage unit information, transfers will not function properly for the following programs: VFA, LHD 317, BAP, and Outbreak.







VFA / LHD 317: Finding Support Through System Transition

If you have questions regarding the 317 or VFA program requirements or the myCAvax system, contact the Provider Call Center at (833) 502-1245 or providercallcenter@cdph.ca.gov, Mon–Fri, 8.00 AM – 5.00 PM PT.









Previously Recorded VFA Trainings: EZIZ Links



The <u>slides</u> and <u>recording</u> of the 'VFA 101 Recertification and Vaccine Ordering in myCAvax' session hosted on <u>Thursday</u>, <u>February 22</u>, <u>2024</u>, are available on <u>EZIZ</u>.

The <u>slides</u> and <u>recording</u> of the 'VFA 102 Vaccine Inventory Management in myCAvax' session hosted on **Thursday**, **February 29**, **2024**, are available on <u>EZIZ</u>.



Vaccine Inventory Management Job Aids




The job aids linked below detail how to complete vaccine inventory reports in myCAvax. You can also access these job aids from the Knowledge Center (myCAvax login required).

| Vaccine Inventory Management Job Aids |
|---------------------------------------|
| Recording Shipment Incidents |
| Recording Temperature Excursions |
| Recording Returns and Waste |
| Recording a Vaccine Transfer |





Bridge Access Program (BAP): Vaccine Allocations Cadence Update



Allocations of BAP COVID-19 vaccine products are refreshed on a biweekly cadence. CDPH receives allocations mid-week and distributes inventory to the LHDs within a few business days.

The most recent CDC allocation refresh was received Wednesday, February 28, 2024.

Doses were added to LHD allocations on Thursday, February 29, 2024.




BAP: CDPH Allocation Plan and Inventory Numbers



Starting the week of **January 29**, **2024**, CDPH began holding back doses to keep on reserve for LHDs with higher demand in their county. LHDs can reach out to the Ordering Leads via chatter (@orderingleads) on myCAvax with questions related to BAP COVID-19 vaccine orders or allocations. LHDs may submit off-cycle allocation requests to the Ordering Leads with a rationale behind their need.

| Initial Allocation to LHJ's | 279,790 |
|-----------------------------|---------|
| Reserve | 100,210 |
| Total State Allocation | 380,000 |





Slide Icon Key

| lcon | Meaning |
|----------|--|
| | This is to label slides that are referencing upcoming or existing functionality and how to use it in the system. |
| | This is to label slides that include important system reminders. |
| Q | This is to label slides that include tips and best practices to improve your system experience. |



Vaccines for Adults (VFA)

Lindsay Reynoso, CDPH



VFA Webinar – Register Now!

Audience: Identified VFA Key Practice Staff + Medical Staff for Adult Patient Population

Wednesday, March 13, 2024, 12 – 1PM PST

Topics: Program Updates, ACIP Update, and a Peer-to-Peer sharing opportunity to hear about Best Practices from Golden Valley Health Centers

REGISTER NOW!





VFA Recertification Part 2 – Now Live!


泣

Complete your Recertification ASAP!

- As of March 7, 180 VFA Sites have completed Recertification
- Recertification Worksheet Now Available
- Recertification must be completed to have access to April Vaccine Ordering
- Recertification must be completed to have access to Vaccine Management Functions (Reporting Transfers, Returns, Waste, Excursions)
- Questions? Contact the Provider Call Center
 - Email: <u>ProviderCallCenter@cdph.ca.gov</u>
 - Phone: (833) 502 1245
 Open Monday Friday, 8AM 5PM



VFA Recertification Part 2



CDPH has prepared a worksheet to gather the required information that you will input into myCAvax to complete recertification "part two." Please download from EZIZ and use the worksheet to prepare. If the information gathered from recertification "part one" in MyVFCvaccines is identical to your VFA program, much of that can be inputted into myCAvax.



VFA Recertification Training

For California VFA Recertification:

| Required for Vaccine Coordinator, Backup, Provider of Record and Designee | | | | | |
|---|----------------------|-------------|--------|--|--|
| VFA Program Requirements | Completed 02/21/2024 | Certificate | Review | | |

For California LHD 317 Program Recertification:

| Required for Vaccine Coordinator, Backup, Provider of Record and Designee | | | | |
|---|----------------------|-------------|--------|--|
| LHD 317 Program Requirements | Completed 02/21/2024 | Certificate | Review | |

VFA providers are to complete the required EZIZ training as soon as possible. CDPH will be reviewing to confirm training completion.

Be sure to complete the required for your designated program



Resources and Q&A

Leslie Amani, CDPH



Vaccine Support

Provider Call Center


Dedicated to medical providers and Local Health Departments in California, specifically addressing questions about State program requirements, enrollment, and vaccine distribution.

- For myCAvax Help Desk inquiries: myCAvax.hd@cdph.ca.gov
- For My Turn Clinic Help Deskinquiries: MyTurn.Clinic.HD@cdph.ca.gov
- For all other inquiries: providercallcenter@cdph.ca.gov
- Phone: (833) 502-1245, Monday through Friday from 8AM-5PM

myCAvax

- Virtual Assistant resolves many questions but will direct you to the Provider Call Center queue for live assistance!
- Knowledge Center houses key job aids and videos that are updated every release. Once logged in, you can access job aids from the myCAvax homepage (or at various places throughout the system) using the links as shown below.

 Need help? View our jobs aids in the Knowledge Center, or contact us.





EZIZ.ORG

Home

Vaccine Programs

Vaccine Management


Storage Units

Temperature Monitoring

Training & Webinars

Clinic Resources

Patient Resources



COVID-19 Provider FAQs

Answers to providers' COVID-19 vaccine and therapeutics questions, updated 3/7/2024!



Q: What is the recommended COVID-19 vaccine schedule for adults age 65 years and older?

A: CDC now recommends that all adults ages 65 years and older receive an additional updated 2023-2024 COVID-19 vaccine dose to help protect against severe disease from COVID-19. For more information, see CDC's Interim Clinical Considerations guidance, as well as the CDPH Updated Timing Guide (Spanish version).



Q: Does diluent for Pfizer COVID-19 vaccine for patients 6 months – 4 years of age need to be ordered separately or does it come with the vaccine?

A: Pfizer will provide diluent with their commercial and VFC vaccines indicated for patients 6 months - 4 years of age. Pfizer has changed the diluent pack size associated with CDC orders of Pfizer COVID-19 Vaccine (2023-2024 Formula) for ages 6 months through 4 years of age [59267-4315-02; COVID-19(Pfizer);(6m-4y);MDV3;10-pk].

Previously vaccine orders for this presentation were supplied with diluent in a 10-pack. Pfizer will now supply diluent in a 25-pack. Please note: One vial of diluent is required to reconstitute one multidose vial of vaccine for individuals 6 months through 4 years of age.

COVID-19 Vaccine and Therapeutics FAQs v.141_03.07.24 **COVID-19 Vaccine and Therapeutics FAQs** For providers administering COVID-19 vaccine and treating COVID-19. Providers may also visit EZIZ COVID-19 Resources for information and updates. Directions: Click on a category to be directed to related FAQs. New and Updated FAQs. COVID-19 Vaccine Access... Bridge Access Program (BAP)... Vaccines For Children (VFC) Program Support & Resources



Provider FAQs on EZIZ

CDPH Provider Webinars and Trainings



Week of March 11, 2024

| | Monday 3/11 | Tuesday 3/12 | Wednesday 3/13 | Thursday 3/14 | Friday 3/15 | | |
|-------------------------------|---|--------------------------|---|--|--------------------------------------|--|--|
| Live Webinars and Training | CA Immunization Coalition (CIC) Ed Hour: Back to the Vax: A Guide to Innoculating Yourself Against Anti-Vax Propaganda 12:00 pm – 1:00 pm | | VFA Webinar: 2024 ACIP Updates & Best Practices for Adult Immunizations 12:00 pm – 1:00 pm | | No Friday Webinar | | |
| View On Demand | CDPH Weekly Provider Arch COVID-19 Crucial Conversa and Slides AIM Vaccine Confidence Too | ations Archived Webinars | Introduction to My Turn Onboarding (v. 1/4/22) Latest Features in My Turn (Requires myCAvax Login) myCAvax Release Notes for LHD and CDP Users (Requires myCAvax Login) | Moderna COVID-19 Vaccine CDC COVID-19 Vaccination Resources Novavax COVID-19 Vaccine Pfizer COVID-19 Vaccine (CO | Clinical & Professional Information | | |
| delp | | | Email: providercallcenter@cdph.ca.gov boarding Email: myturnonboarding@cdph.ca. | Immunization California's General Immunization RSV Immunization Resources | | | |



COVID-19 Treatments

COVID-19 Vaccination Resources

Mpox Vaccination Resources

Mpox: Email: stdcb@cdph.ca.gov

myCAvax: Help Desk Email: mycavax.hd@cdph.ca.gov

CDPH Provider Webinars and Trainings



Week of March 18, 2024 - DRAFT

| | Monday 3/18 | Tuesday 3/19 | Wednesday 3/20 | Thursday 3/21 | Friday 3/22 |
|-------------------------------|--|--------------------------|---|---|--|
| Live Webinars and Training | | | | | CDPH Immunization Updates for Providers 9:00 am - 10:30 am |
| View On Demand | CDPH Weekly Provider Arch COVID-19 Crucial Conversa and Slides AIM Vaccine Confidence To | ations Archived Webinars | Introduction to My Turn Onboarding (v. 1/4/22) Latest Features in My Turn (Requires myCAvax Login) myCAvax Release Notes for LHD and C Users (Requires myCAvax Login) | Moderna COVID-19 Vaccination CDC COVID-19 Vaccination Resources Novavax COVID-19 Vaccin Pfizer COVID-19 Vaccine (Covid-19) | Clinical & Professional e Information |
| lelp | *CDPH Provider Call Center: 1-833-502-1245, M-F 8am-5pm Email: providercallcenter@cdph.ca.gov My Turn: Help Desk Email: myturn.clinic.hd@cdph.ca.gov Onboarding Email: myturnonboarding@cdph.ca.gov | | | California's General Immunization RSV Immunization Resources | |

myCAvax: Help Desk Email: mycavax.hd@cdph.ca.gov

Mpox: Email: stdcb@cdph.ca.gov

COVID-19 Vaccination Resources **COVID-19 Treatments** Mpox Vaccination Resources



California's Digital Vaccine Record (DVR)



Welcome to the Digital Vaccine Record (DVR) portal

To get a digital copy of your vaccine record, just enter a few details below. You can get a link to your COVID-19 Vaccine Record with a QR code or your California Immunization Record. Save it on your phone and use it as proof of vaccination wherever you go.

If you are a parent or guardian and have multiple vaccine records associated with a single cell phone number or email address, enter each Digital Vaccine Record request separately.

NOTE: It is possible that some or all vaccine doses you received were not reported to the California Immunization Registry (CAIR), and therefore your Digital Vaccine Record may not be complete. If your record is incomplete, please ask your provider to submit your vaccine information to CAIR so we can update your record. It's important that you provide up to date information about yourself (phone, email, first and last name) to your provider so you can access your complete record.

If you received your vaccinations from a federal agency (e.g., Department of Defense, Indian Health Services, or Veterans Affairs), you may need to contact those agencies for assistance with your vaccination record.

If you have questions about your vaccination record, visit our FAQ.



COVID-19 Therapeutics Resources



Type of Support

Clinical Guidance

For general Therapeutics questions, please email: COVIDRxProviders@cdph.ca.gov

CDPH COVID-19 Treatments Webpage (provides general information for healthcare providers, allocations, distribution and ordering, drug facts sheets, and additional resources)

CDPH COVID-19 Treatments Job Aid (questions and answers for the public on COVID-19 therapeutics)

COVID-19 Therapeutics Best Practices Checklist (testing, prescribing, dispensing, and more)

Frequently Asked Questions document for clinics, providers, and pharmacists

Finding Providers and Test-to-Treat Sites

COVID-19 Therapeutics Locator (arcgis.com)

Test-to-Treat (hhs.gov)



LHJ Therapeutics SharePoint

Primary source for recorded webinars, slides, datasets and HPOP reporting information. (For access, email JEOCuser54@cdph.ca.gov)

- Therapeutic Weekly Email Update files (SharePoint)
- CDPH Therapeutics HPoP Account Verification & Reporting information



Questions


For general CDPH Therapeutics questions, please email COVIDRxProviders@cdph.ca.gov
For ordering, program inquiries, signing up new HPOP Accounts: please e-mail CDPHTherapeutics@cdph.ca.gov



Questions

During today's webinar, please use the Q&A panel to ask your questions so CDPH subject matter experts can respond directly.





Note: CDPH SMEs and Panelists on today's call will do their best to answer all questions related to today's updates.



Upcoming CDPH Webinar Opportunity

CDPH Immunization Updates for Providers

Next session: Friday, March 22, 2024

9AM - 10:30AM



